Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beigene | B3 | Healthcare | Biotechnology & Medical Research | R$190.97B | -179.4x | -2.94 | R$68.74 | 8.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| IQVIA Holdings BDR | B3 | Healthcare | Biotechnology & Medical Research | R$180.19B | 27.6x | -2.58 | R$258 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| BioNTech SE | B3 | Healthcare | Biotechnology & Medical Research | R$147.44B | -66.9x | -2.11 | R$38.40 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Ascendis Pharma AS | B3 | Healthcare | Biotechnology & Medical Research | R$64.86B | -37x | -0.79 | R$71.18 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| BioTechne | B3 | Healthcare | Biotechnology & Medical Research | R$47.21B | 117.1x | -2.03 | R$9.99 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Biomm On | B3 | Healthcare | Biotechnology & Medical Research | R$900.57M | -13.3x | -0.43 | R$7.10 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |